目的 探討續(xù)斷壯骨膠囊聯(lián)合依降鈣素治療骨質(zhì)疏松的臨床療效。方法 選取2020年9月—2022年5月秦皇島市第一醫(yī)院收治的128例骨質(zhì)疏松癥患者,隨機(jī)分為對(duì)照組(64例)和治療組(64例)。對(duì)照組患者肌肉注射依降鈣素注射液,10 U/次,2次/周。在對(duì)照組的基礎(chǔ)上,治療組口服續(xù)斷壯骨膠囊,2粒/次,3次/d。兩組患者用藥24周。觀察兩組患者臨床療效,比較治療前后兩組患者患者癥狀緩解時(shí)間,視覺(jué)模擬疼痛評(píng)分法(VAS)評(píng)分,腰椎L2、腰椎L4、股骨頸的骨密度(BMD),血清炎性因子胰島素樣生長(zhǎng)因子-1(IGF-1)、抗酒石酸酸性磷酸酶-5b(TRACP-5b)、白細(xì)胞介素-6(IL-6)和骨堿性磷酸酶(BSAP)水平,及不良反應(yīng)情況。結(jié)果 治療后,治療組患者臨床有效率為(98.43%),明顯高于對(duì)照組(84.38%,P<0.05)。治療后,治療組癥狀緩解時(shí)間均早于對(duì)照組(P<0.05)。治療后,兩組患者VAS評(píng)分明顯降低,而腰椎L2、腰椎L4、股骨頸的骨密度(BMD)均高于治療前(P<0.05),且治療組骨疼痛程度及骨密度均明顯好于對(duì)照組(P<0.05)。治療后,兩組血清炎性因子IL-6、TRACP-5b水平均低于治療前,而IGF-1和BSAP水平高于治療前(P<0.05),且治療組明顯好于對(duì)照組(P<0.05)。治療后,治療組不良反應(yīng)發(fā)生率(7.81%)明顯低于對(duì)照組(12.50%,P<0.05)。結(jié)論 依降鈣素聯(lián)合續(xù)斷壯骨膠囊治療效果確切,對(duì)骨質(zhì)疏松臨床癥狀緩解明顯,骨疼痛狀態(tài)減弱,血清標(biāo)志物水平顯著改善。

Objective To explore the therapeutic effect of Xuduan Zhuanggu Capsules combined with calcitonin in treatment of osteoporosis.Methods Patients(128 cases) with osteoporosis in First Hospital of Qinhuangdao from September 2020 to May 2022were randomly divided into control(64 cases) and treatment(64 cases) group. Patients in the control group was intramuscular injection administered with Elcatonin Injection, 10 U/time, twice weekly. Patients in the treatment group were po administered with Xuduan Zhuanggu Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 24 weeks.After treatment, the clinical evaluation was evaluated, and the relief time of symptom, VAS scores, the BMD of lumbar L2, lumbar L4, neck of femur, and the levels of serum IL-6, TRACP-5b, IGF-1 and BSAP, and adverse reaction in two groups before and after treatment were compared.Results After treatment, the clinical effective rate of the treatment group was(98.43%), which was significantly higher than that of the control group(84.38%, P<0.05). After treatment, the time of symptom relief in the treatment group was earlier than that in the control group(P<0.05). After treatment, the VAS score in two groups were significantly decreased,while the bone mineral density(BMD) of lumbar L2, lumbar L4 and femoral neck were higher than those before treatment(P<0.05),and the degree of bone pain and bone mineral density in the treatment group were significantly better than those in the control group(P<0.05). After treatment, the levels of serum inflammatory factors IL-6 and TRACP-5b in two groups were lower than those before treatment, while the levels of IGF-1 and BSAP were higher than those before treatment(P<0.05), and which in the treatment group was significantly better than those in the control group(P<0.05). After treatment, the incidence of adverse reactions in the treatment group(7.81%) was significantly lower than that in the control group(12.50%, P<0.05).Conclusion The therapeutic effect of calcitonin combined with Xuduan Zhuanggu Capsules is definite, the clinical symptoms of osteoporosis are relieved obviously, the state of bone pain is weakened, and the level of serum markers is significantly improved.

R977

河北省醫(yī)學(xué)科學(xué)研究課題計(jì)劃(20221612)